3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation
With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.
Overview
Over the past year, Bristol Myers Squibb (NYSE: BMY) shares surged around 42.5%. Yet even after this strong performance, shares remain at the low end of the company's long-term valuation range.
Put simply, investors remain on the fence about the company's ability to overcome major upcoming patent expirations through the launch of new drug products. However, for patient investors, this uncertainty could work in your favor.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.